Washington University Medical Center
Robert D. Schreiber, Ph.D. earned his B.A. degree in Chemistry from State University of New York at Buffalo in 1968 and his Ph.D. in Biochemistry and Immunology from the same institution in 1973. He received his postdoctoral training in immunology at the Research Institute of Scripps Clinic in La Jolla, California from 1973-1976, and was then appointed to the Scripps faculty in 1976 where he rose to the rank of Tenured Associate Member. In 1985, Schreiber was recruited to Washington University School of Medicine in St. Louis, Missouri as Professor of Pathology and Immunology and Professor of Molecular Microbiology and, in 1990, became the Alumni Endowed Professor of Pathology and Immunology. Schreiber is currently the Andrew M. and Jane M. Bursky Distinguished Professor in the Department of Pathology and Immunology at Washington University School of Medicine; Founding Director of the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; and co-leader of the Tumor Immunology Program of Washington University’s Siteman Comprehensive Cancer Center. He is an Extramural Member Researcher of the Parker Institute for Cancer Immunotherapy, an Associate Director of the Scientific Advisory Board to the Cancer Research Institute, and a member of the Board of Scientific Advisors to the National Cancer Institute. Schreiber is a co-founder of two biotech companies: Jounce Therapeutics (Boston MA) and Neon Therapeutics, Inc (Cambridge, MA). He is also a member of Scientific Advisory Boards for A2 Biotherapeutics, BioLegend, Constellation Pharmaceuticals, NGM Biopharmaceuticals, Sensei Biotherapeutics, and the Osteosarcoma Institute.
Schreiber’s research focuses on two areas: (1) the cell biology of interferon-gamma and its receptor and (2) elucidating the cellular and molecular mechanisms underlying natural and therapeutically induced immune responses to developing and established cancers. Schreiber described the process of cancer immunoediting, pioneered the use of genomics approaches to define the neoantigenic targets in cancers, defined underlying mechanisms involved in immune checkpoint cancer therapy and was one of the first to use an immunogenomics approach to develop individualized cancer vaccine therapies.
Robert Schreiber has authored more than 300 peer reviewed and invited publications and has received many honors for his work. Among the more recent are the 2014 Lloyd J. Old Prize in Cancer Immunology awarded jointly by the American Association for Cancer Research and the Cancer Research Institute and the 2017 Balzan Prize (shared with James Allison): Immunological Approaches in Cancer Therapy. Schreiber is a Fellow of the American Association for the Advancement of Science, a fellow of the American Association for Cancer Research, a member of the American Academy of Arts and Sciences and a member of the U.S. National Academy of Sciences.